Clinical Trials – Page 2 – Medical Alley Association

Clinical Trials

Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer

Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments Vyriad to receive upfront payment and equity investment from Regeneron TARRYTOWN, N.Y., and ROCHESTER, Minn. (November 6, 2019) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Vyriad, Inc. today announced a research collaboration and option […]

Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Clinical Trial to Leverage Novel Digital Endpoints

The 100+ site global Phase 3 clinical trial is the first-of-its-kind to leverage continuous multivariate wearable sensor data and Artificial Intelligence-based analytics The landmark trial endpoint approach aligns with commentary at a recent FDA Public Workshop on biomarkers for heart failure clinical trials To date, hundreds of thousands of hours of continuous multivariate sensor data […]

SilkTech Biopharmaceuticals Completes Enrollment of Phase 2B Clinical Trial of SDP-4 for the Treatment of the Signs and Symptoms of Dry Eye Disease

MINNEAPOLIS, MN— August 6, 2019 — SilkTech Biopharmaceuticals, a biotechnology company focused on the development of novel therapies to treat Dry Eye Disease (DED), today announced the completion of their Phase 2B clinical trial enrollment to assess the safety and efficacy of the company’s SDP-4 ophthalmic eye-drop formulation to treat the signs and symptoms of DED. […]

SilkTech Biopharmaceuticals’ IND Submission Cleared by FDA; Phase 2 Clinical Trial Initiated for Patients with Dry Eye Disease

Milestone Results in $6.2 Million in Additional VC Funding Minneapolis, MN – April 16, 2019 – PRWeb – SilkTech Biopharmaceuticals, a company devoted to improving eye health through the development of silk-derived protein biotherapeutics for the targeted treatment of Dry Eye Disease (DED), today announced the company has received clearance of its Investigational New Drug […]

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1) EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2) EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2) THOUSAND OAKS, […]

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER